News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
BioNxt Solutions Inc. expands next-gen product pipeline targeting autoimmune diseases & longevity market. Innovative drug delivery systems show promise in major high-growth markets -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. initiates nationalization process for sublingual anticancer drug patents for autoimmune neurodegenerative diseases. Positive report from European Patent Office on patentability -